Algorithms are components
Necessary, proprietary and scientifically strong—but insufficient alone.
The central thesis
Drug discovery will not be won by the best isolated algorithm. It will be won by the system that learns fastest
Models organise scientific reality
They connect data, mechanisms, assumptions and uncertainty.
ADAPT turns models into decisions
Every specialised tool contributes to the same programme objective.
Experiments close the loop
Physical evidence improves the next model and the next molecule.
What SoftMining has built
Three engines. One integrated company
Defensibility lies in the connection between scientific intelligence, an operating architecture and direct experimental execution.
Scientific intelligence
Proprietary algorithms become programme-specific models for evidence, targets, molecular properties, structural reasoning and uncertainty.
ADAPT operating architecture
ADAPT preserves the rationale behind hypotheses, calculations, experiments and decisions across the complete path.
Open the technical ADAPT page →
Physical discovery engine
The computational workflow interfaces directly with SYNTHEX robotic synthesis, assays and pharmacology.
Open the technical SYNTHEX page →
Models, rethought
The question is not “Will it bind?” It is “Is it worth making?”
A molecule becomes valuable only when biological, technical, experimental and economic conditions converge.
Activity & selectivityADMET & safetySynthesis & formulationPatentabilityCost & timeEvidence confidence
ADAPT / GLOBAL AI CORE
Many specialised tools.
One holistic decision system
ADAPT is not a catalogue of point solutions. It coordinates evidence, models, experiments and expert judgement while preserving context in one scientific memory.
ONE SCIENTIFIC MEMORYADAPTGlobal AI core
DeepSageEvidence
Target reasoningBiology
Structural models3D context
SIMILISSimilarity
Pareto optimisationTrade-offs
ADMETDevelopability
SYNTHEXSynthesis
AssaysValidation
PharmacologyTranslation
Expert reviewDecisions
Frame→Understand→Design→Make & test→Learn
The physical loop
AI becomes defensible when it touches chemistry
Synthesis automation is not unique by itself. SoftMining’s advantage is the integration of custom robotic modules, magnetic solid supports and model-guided experimental choice.
Custom-configured robotic modules
Robots are configured around the chemistry, handling and analytical requirements of the library—not presented as a generic automation product.
Functionalised magnetic nanoparticle platform
Magnetic solid supports enable parallel handling, reaction sequences, washing and separation across miniaturised synthesis workflows.
Integrated synthesis selection
ADAPT prioritises what to make and what to test so that production capacity is directed towards the highest-information experiments.
SELECT → MAKE → SEPARATE → TEST → LEARNDifferentiation comes from integration, not from robotics alone.
Product pipeline
Agnostic across discovery problems.
Concrete in asset creation
SoftMining can operate across targets and therapeutic areas while advancing a real internal and co-development pipeline.
PLATFORM-AGNOSTIC BY DESIGNAsset-generating in practice.
New therapeutic strategies
for aggressive brain tumours
Discovery programme for
molecularly diverse disease
Therapeutic programme for
metabolic liver disease
First discovery programme
focused on bacterial infection
Second programme expanding
the antibacterial pipeline
Target-driven programme for
ADAR-mediated RNA editing
8products in pipeline
6molecules entering preclinical
Targets, indications and structures are intentionally not disclosed on the public site.
How value compounds
From scientific service to portfolio value
The same infrastructure resolves partner decisions, scales as an enterprise platform and creates proprietary or co-developed pharmaceutical assets.
Integrated discovery programmes
Target intelligence, molecular design, synthesis and validation solve a defined R&D bottleneck.
Services and partnershipsADAPT as recurring infrastructure
Configured workflows, scientific memory and enterprise access extend across programmes.
SaaS and APIPipeline and Academic Foundry
Proprietary programmes, co-development and funded academic validation create licensable assets.
Milestones, licensing and IPEvidence of execution
The architecture is already producing proof
Proprietary science, intellectual property, international research, platform adoption and a growing preclinical pipeline.
19proprietary algorithms
5+2patents filed / filing
8products in pipeline
6molecules entering preclinical
6European projects
>120kbiomedical app users
$2.1Mfunding raised
Top100IRCAI / UNESCO AI solution
Credibility
Selected collaborations & relationships
Academic, industry, technology and innovation relationships already represented in SoftMining's approved public materials.
Choose your path
Three audiences.
Three focused stories
The central system remains the same; the narrative changes with the decision-maker.
01 / CAPITAL
Investors
Market, moat, growth, pipeline economics and the Series A.
Open the investor deck →02 / DISCOVERYPharma & biotech
Capabilities, workflow, deliverables and partnership models.
Explore the workflow →03 / RESEARCHAcademic Foundry
Assessment, funding, consortium building, validation and shared value.
Enter the Foundry →